Open Label Phase Ib/II, Multicenter Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC

Trial Profile

Open Label Phase Ib/II, Multicenter Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Lumretuzumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 24 Nov 2016 Status changed from suspended to discontinued. As per results published in the European Clinical Trials Database results record, this trial was discontinued due to a strategic decision taken by the sponsor to stop further development of RO5479599. This trial was conducted in Spain, Canada and Denmark. Planned trial sites for this trial also included Korea, Netherlands, UK, France, Germany, Norway and USA
    • 18 Nov 2016 This trial has been completed in Spain (end date: 14 Mar 2016).
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top